INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback